The finding that troglitazone and its derivative Δ2-troglitazone effectivelyinhibit TGF-β release suggests readily available PPARγ activators and structurally related PPARγ inactive compounds ascandidate drugs for adjuvant glioma therapy. This evidence concerns the gene PPARG and central nervous system cancer.